Dermata Therapeutics Inc DRMA stock was trading higher Friday after the company shared some exciting news. The firm announced the issuance of a new patent in Japan for its DMT410 program, particularly focusing on addressing hyperhidrosis.

The patent, titled “Compositions for the treatment of skin conditions” (Japanese Patent No. 7395576), enhances Dermata’s intellectual property for DMT410 for hyperhidrosis and lays the foundation for additional protections for different indications.

According to Gerry Proehl, Dermata’s Chairman, President, and CEO, “We believe this patent issuance further validates DMT410’s novel concept to easily deliver botulinum toxin topically instead of requiring patients to receive multiple injections.”

Proehl added, “We also believe there are opportunities to use DMT410 to treat numerous aesthetic skin conditions like reducing pore number and size, decreasing sebum production, and reducing fine lines and wrinkles, all while enhancing the look and quality of facial skin.”

Proehl also suggested that “this new patent could aid us in our partnership discussions with a company that has a botulinum toxin to further develop the DMT410 program for multiple indications.”

DMT410 represents the company’s combination treatment regimen. It utilizes the unique mechanical features of the Company’s Spongilla technology to facilitate the intradermal delivery of botulinum toxin by topical application rather than through multiple injections with a needle.

The company has finished proof-of-concept Phase 1 clinical trials using DMT410 in combination with widely used BOTOX for primary axillary hyperhidrosis and various aesthetic skin conditions. Both studies demonstrated promising efficacy results and appeared safe and well tolerated by patients.

Price Action: DRMA shares surged 31% to 80 cents at last check Friday.

Now Read: Short Sellers’ Nightmare: $195B Evaporates In 2023’s Market Surge

Photo: Shutterstock